If a company shows a lot of potential, investors are often willing to pay a premium and take on some risk in exchange for ...

Head-to-Head Phase 3 Trial Compared to Pembrolizumab Initiated HONG KONG, Sept. 15, 2024 /PRNewswire/ — At the 2024 European ...

Summit Therapeutics and Akeso published results for the Phase III HARMONi-2 trial, which tested ivonescimab, a bispecific ...

Summit Therapeutics' ivonescimab shows a significant PFS improvement over pembrolizumab in NSCLC. Read why I'm bearish on ...

Summit Therapeutics' ivonescimab poised for FDA approval, with the potential to disrupt the oncology market. Read more on ...

Data from a Phase 3 study has revealed that ivonescimab demonstrates a statistically significant and clinically meaningful ...

Summit Therapeutics’ ivonescimab has the potential to challenge Merck’s blockbuster checkpoint inhibitor in non-small cell ...

Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that data for the novel, potential ...

Summit Therapeutics acquired rights to ivonescimab outside of China and Australia. With Keytruda sales up around $25 billion ...

Some patients with non-small cell lung cancer saw a 49% reduction in the risk of disease progression or death with ...

Keytruda's dominance as a mainstay in cancer immunotherapy isn’t threatened by an experimental Chinese drug, a top Merck ...